DBV Technologies (NASDAQ:DBVT) Shares Gap Down – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $14.70, but opened at $14.22. DBV Technologies shares last traded at $14.33, with a volume of 25,982 shares changing hands.

Analyst Ratings Changes

A number of equities analysts recently commented on DBVT shares. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Citizens Jmp upped their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Finally, Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Price Performance

The stock has a market capitalization of $847.95 million, a price-to-earnings ratio of -4.08 and a beta of -0.95. The business has a fifty day moving average of $17.14 and a 200 day moving average of $19.48.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. On average, equities research analysts expect that DBV Technologies S.A. will post -0.38 EPS for the current year.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its position in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the last quarter. Truvestments Capital LLC boosted its position in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares during the period. Allworth Financial LP purchased a new position in shares of DBV Technologies during the 4th quarter worth approximately $32,000. Royal Bank of Canada acquired a new stake in DBV Technologies in the 4th quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in DBV Technologies in the 4th quarter valued at approximately $115,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.